KHONDRION BV

Their core work

Khondrion is a Dutch clinical-stage biotechnology company developing therapies for mitochondrial diseases — a group of rare, debilitating genetic disorders with no approved treatments. Their lead compound KH176 has progressed through Phase 2b clinical trials, with both EMA and FDA orphan drug designation. The company combines deep expertise in mitochondrial biology with drug development capability, positioning itself at the intersection of rare disease science and pharmaceutical commercialization.

What they specialise in

How they've shifted over time

Khondrion's H2020 trajectory shows a textbook biotech maturation arc. Their early projects (2015-2016) were collaborative research efforts — SysMedPD explored systems medicine approaches to mitochondrial Parkinson's, and REMIX investigated fundamental mitochondrial gene expression. By 2018, they had shifted decisively to clinical drug development, coordinating the €2.3M KHON2bTREAT project to push their lead compound KH176 through Phase 2b trials and pursue market access.

Khondrion is moving from research participation toward independent drug commercialization, suggesting future collaborations will center on clinical trials, market access, and manufacturing scale-up for rare disease therapeutics.

How they like to work

Khondrion operates as both partner and leader depending on project maturity. In research-stage projects (SysMedPD, REMIX), they contributed as participants in larger consortia, absorbing scientific knowledge. When ready for clinical translation, they took the coordinator role (KHON2bTREAT), indicating confidence in managing their own pipeline. With 17 partners across 7 countries, they maintain a broad European network typical of a biotech building toward commercialization.

Khondrion has collaborated with 17 unique partners across 7 European countries, building a network that spans academic research groups and clinical partners relevant to rare disease drug development. Their Netherlands base connects them to a strong Dutch biotech ecosystem.

What sets them apart

Khondrion occupies a rare niche: a small company with both deep mitochondrial biology expertise and active clinical-stage drug development for mitochondrial diseases, a therapeutic area with virtually no approved treatments. Their dual EMA/FDA orphan drug designation for KH176 signals regulatory credibility that few European biotech SMEs in this space can match. For consortium builders, they offer the rare combination of scientific depth in mitochondrial pathways and real-world pharmaceutical development experience.

Highlights from their portfolio

• KHON2bTREAT
  Their largest project (€2.3M, coordinator role) — represents the critical leap from research to Phase 2b clinical trials for their orphan drug KH176 targeting mitochondrial disease.
• SysMedPD
  A €662K participation in systems medicine for mitochondrial Parkinson's disease, connecting Khondrion's mitochondrial expertise to neurodegenerative disease applications.